Aclaris Therapeutics, Inc. (0H8T.L)

1.2201 +0.0051 (+0.42%) As of 06:54PM BST. Market open.

Aclaris Therapeutics, Inc.

701 Lee Road
Suite 103
Wayne, PA 19087
United States
484 324 7933
https://www.aclaristx.com

Sector(s): 
Industry: 
Full-time employees: 86

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Neal S. Walker D.O., M.D.	Co-Founder, President, Chairman & Interim CEO	955.69k	N/A	1970
Dr. Joseph Monahan Ph.D.	Chief Scientific Officer	600.02k	N/A	1957
Mr. Kevin Balthaser	Chief Financial Officer	N/A	N/A	1988
Mr. Matthew Rothman J.D.	General Counsel & Corporate Secretary	N/A	N/A	N/A
Dr. Jon Jacobsen Ph.D.	Senior Vice President of Chemistry	N/A	N/A	N/A
Mr. James Loerop	Chief Business Officer	N/A	N/A	1965

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Corporate governance

Aclaris Therapeutics, Inc.’s ISS governance QualityScore as of 1 April 2024 is 8. The pillar scores are Audit: 8; Board: 8; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.